CELSION REPORTS THERMODOX DATA

A A

Celsion has reported data on its trial of ThermoDox, a proprietary heat-activated liposome containing doxorubicin HCI.

Queen Mary Hospital in Hong Kong has begun to participate as an additional site in the company's ongoing Phase I dose-escalation study investigating the use of ThermoDox, in combination with radiofrequency ablation to treat liver cancer. Together with a U.S. site -- the National Cancer Institute in Bethesda, Md. -- 14 patients have now been treated in the study, at single doses as high as 50 mg per meter squared.